ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

11:00AM-11:50AM: Abstract Number: 2027

Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

11:00AM-11:50AM: Abstract Number: 2023

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

11:00AM-11:50AM: Abstract Number: 2026

Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

11:00AM-11:50AM: Abstract Number: 2025

Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies

Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

11:00AM-11:50AM: Abstract Number: 2052

Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease

Vasculitis – ANCA-Associated (2048–2052)

11:00AM-11:50AM: Abstract Number: 1990

Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

11:00AM-11:50AM: Abstract Number: 2051

Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database

Vasculitis – ANCA-Associated (2048–2052)

11:00AM-11:50AM: Abstract Number: 1992

Longitudinal Evaluation of Axonal Dysfunction, Neuronal Markers and Serum Cytokines in Childhood-onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

11:00AM-11:50AM: Abstract Number: 2049

Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated (2048–2052)

11:00AM-11:50AM: Abstract Number: 1989

NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin

Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

11:00AM-11:50AM: Abstract Number: 1979

Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients

Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:00AM-11:50AM: Abstract Number: 1981

Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study

Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:00AM-11:50AM: Abstract Number: 1978

Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy

Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:00AM-11:50AM: Abstract Number: 1982

Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus

Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:00AM-11:50AM: Abstract Number: 1988

Skin Disease More Recalcitrant to Intervention Than Muscle Disease: A Long-Term Prospective Study of 184 Children with Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].